List view / Grid view
8 December 2012 | By Bristol-Myers Squibb Company
Results of the Phase 3 AMPLIFY-EXT trial...
28 November 2012 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc..
20 November 2012 | By Bristol-Myers Squibb Company
The EC has approved ELIQUIS®...
19 November 2012 | By Cystic Fibrosis Foundation
CFFT announced a major expansion of its research collaboration with Pfizer...
19 November 2012 | By Pfizer
Top-line results of a Phase 3 study...
16 November 2012 | By Pfizer
Pfizer Inc., announced top-line results of a double-blind, placebo-controlled, Phase 3 study...
12 November 2012 | By Amgen
Amgen and Pfizer announced that results from several Enbrel® (etanercept) studies...
7 November 2012 | By Pfizer
Auxilium Pharmaceuticals, Inc., and Pfizer are amending their collaboration agreement...
6 November 2012 | By Pfizer
The U.S. FDA has approved XELJANZ®...
1 November 2012 | By Bristol-Myers Squibb Company
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer announced a clinical collaboration agreement...
In this Non-Destructive Material Identification In-Depth Focus: An implementation perspective on handheld Raman spectrometers for the verification of material identity; Portable Raman spectroscopy for pharmaceutical counterfeit detection; Ask the Experts...
24 October 2012 | By Pfizer
Conditional marketing authorization for XALKORI® in the EU granted...
22 October 2012 | By Pfizer
Pfizer has announced its intention to acquire NextWave Pharmaceuticals...
17 October 2012 | By Pfizer
In treatment-naïve patients with advanced renal cell carcinoma...
11 October 2012 | By Pfizer
“These top-line data provide evidence of the long-term safety of ALO-02..."
